Novo Nordisk has released more data on its much-watched diabetes drug liraglutide. In a head-to-head trial against exenatide (Byetta), liraglutide, a human GLP-1 analog, was more effective at improving blood glucose control than Byetta. "Patients treated with once-daily liraglutide achieved better blood glucose control and also had less minor hypoglycemia than those treated with exenatide," said Lawrence Blonde, MD, Director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes, and Metabolism at the Oxford Center in New Orleans. Fasting plasma glucose was also reduced significantly more with liraglutide. The drug is also in Phase II trials for obesity.
- here's the liraglutide release [1]
Related Articles:
Novo Nordisk - Biotech Market Share Report [2]
Developers advancing a new slate of weight loss drugs [3]
Novo: no pancreatitis risk linked to Liraglutide [4]
Links:
[1] http://www.fiercebiotech.com/press-releases/new-data-head-head-phase-3-trial-demonstrate-liraglutide-more-effective-exenatide-tre
[2] http://www.fiercebiotech.com/special-reports/novo-nordisk-biotech-marketshare-report
[3] http://www.fiercebiotech.com/story/developers-advancing-new-slate-weight-loss-drugs/2008-07-29
[4] http://www.fiercebiotech.com/story/novo-no-pancreatitis-risk-linked-liraglutide/2007-10-17